On October 11, Yunnan Baiyao issued the "Announcement on the Appointment of Senior Management Personnel", appointing Li Shengli as its senior vice president. Li Shengli has held important positions in many pharmaceutical companies, including general manager, president, CEO, and chairman of Jiangsu Wanbang Pharmaceutical Marketing Biochemical Oncology Division, co-president, president, and chairman of Jiangsu Fosun Pharmaceutical Sales Co., Ltd., assistant to the president, vice president, senior vice president, executive president, and chief development officer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. The joining of Li Shengli once again verified the change in Yunnan Baiyao's talent training model, from internal talent training to the "internal training + external introduction" dual-channel talent model, to create a high-quality talent team that meets its future development needs.

Pharmaceutical companies have established their own talent training and selection system, and the company and employees understand each other, have high loyalty, and there is almost no transition period for selection. However, due to changes in the market and environment, it is no longer realistic for pharmaceutical companies to select talents from within the company for growth. To develop new businesses and new markets, companies need to introduce talents from outside.

The current pharmaceutical market is highly competitive, with the homogeneity of generic drugs, market transparency, and information disclosure. The importance of talent is becoming increasingly prominent. Talent, as a core resource in modern enterprise management, is increasingly valued. Key talents are an important factor in helping pharmaceutical companies develop steadily, and the "key talent battle" of pharmaceutical companies has escalated. When hiring senior executives, Yunnan said that the establishment of a talent team has injected fresh blood into its management improvement, new business incubation, business development, digital construction and other fields, and enhanced its new business development capabilities.

According to incomplete statistics from Cyber Blue, Yunnan Baiyao last issued a personnel change announcement on August 26, when it appointed Chen Shi and He Tao as senior vice presidents. Both senior vice presidents were introduced from outside. Chen Shi has served as an automation engineer at Liaoyang Spring Factory under China First Automobile Group Co., Ltd., a research and development engineer and expansion project manager of Midea Group Co., Ltd., and a human resources expert at Huawei Technologies Co., Ltd.; He Tao has served as deputy general manager of the Finance Department of China Telecom Yunnan Company (in charge of work) and general manager of the Marketing Department; secretary of the Party Committee and general manager of China Telecom Yuxi Company, etc.

Unlike other executives, vice presidents of pharmaceutical companies can often help companies control strategies, supervise product quality, manage sales teams, coordinate internal departments, and cooperate with other companies. The changes in Yunnan Baiyao's development strategy can be seen from the appointment of several vice presidents of Yunnan Baiyao.

In addition to Yunnan Baiyao's core drugs and oral care product groups, Yunnan Baiyao has established business layouts in multiple fields such as natural medicines, Chinese herbal medicine slices, specialty medicines, medical devices, health daily chemical products, and health foods, realizing the transformation from a traditional Chinese medicine manufacturing company to a modern health company. During his tenure as executive president and chief development officer of Fosun Pharma, Li Shengli was committed to the development, licensing and promotion of innovative drugs in the field of oncology.

During his tenure as co-CEO and president of Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., he implemented the development strategy of "two wings flying together, three lines synergizing" and built a marketing team covering the whole country. Among them, Rx, business, OTC, Internet, MA, KA, GA and other teams are Wanbang's unique special teams in Fosun Pharma's marketing platform, and many varieties have occupied the first place in the domestic market share. Li Shengli, who is good at marketing, believes that prescription drugs, western medicine, and hospital markets are the core keywords from his past experience. However, this does not seem to fit the impression Yunnan Baiyao has left on the public. In contrast, Yunnan Baiyao has new talent demands in the new development stage.

In 2022, Yunnan Baiyao will enter the field of nuclear medicine. The 2024 semi-annual report shows that its INR101 diagnostic nuclear medicine project for PET/CT imaging diagnosis of suspected prostate cancer patients has obtained clinical approval and completed Phase I clinical trials. The development of nuclear medicine is optimistic in the market. According to Fortune Business Insights, the global nuclear medicine market size will grow from US$8.4 billion in 2023 to US$30.4 billion in 2030. Many pharmaceutical companies have increased their investment in this blue ocean market. With the addition of more talents, Yunnan Baiyao is expected to achieve faster development.

On March 28, the Yunnan Baiyao Board of Directors reviewed and approved the "2024-2028 Strategic Planning Outline", which sorted out the development goals and directions, paths and methods for the next five years. It will firmly continue to deepen the industry foundation of "medicine", promote various businesses to focus on strengthening the industry's leading position in the advantageous fields of the big health industry, and use this as the core to promote the creation of new business growth points. Today, Yunnan Baiyao Pharmaceutical Business Group has determined the strategic positioning of "the leading brand in the management of all fields of trauma pain", and will focus on the pain strategy and break through key products; the health products business group will focus on the development of oral health products in the second half of the year, with gum protection as the core, and launch exclusive oral care products for different channels and consumer groups.

The 2024 semi-annual report shows that Yunnan Baiyao's revenue is 20.455 billion yuan, an increase of only 0.72% year-on-year, which is nearly 12 percentage points slower than the same period in 2023; Pien Tze Huang's revenue is 5.651 billion yuan, a year-on-year increase of 12%. The pressure on the consumer market has brought considerable challenges to Yunnan Baiyao. In the case of a slow recovery in the overall consumer goods field, the market has put forward higher requirements for companies to maintain keen insight and innovation, and to manage and empower channels and terminals more finely. Pharmaceutical companies need talented leadership to develop new strategies. Yunnan Baiyao is looking for new growth points in performance by adjusting its senior management team.

https://mp.weixin.qq.com/